美女av爆操国产_五月天丁香七月深爱激情网_日韩欧美内地福利_国产麻豆精品_亚洲一区乱码精品中文_亚洲第一乱码字幕小综合_国产剧情精品91一区二区_嗯啊羞羞视频在线观看动漫_影音先锋AV成人电影_日韩在线视频导航

"A randomized, single-blind, placebo-controlled, single-center, single-dose-escalation, and multi-dose-escalation phase I trial evaluated the safety, tolerability, pharmacokinetic, and preliminary pharmacodynamic characteristics of subcutaneous RBD7022 in subjects with normal or elevated LDL cholesterol" is ongoing.

RBD 7022 is a GalNAc-conjugated siRNA against PCSK9 (proprotein convertase subtilisin/kexin type 9) for the treatment of hyperlipidemia by lowering LDL-C (low-density lipoprotein cholesterol). The drug reduces LDL-R (low-density lipoprotein receptor) lysosomal degradation and increases the number of LDL-R on the surface of liver cells, thus reducing LDL-C levels in the blood. 

In September 2022, the product received approval from the National Medical Products Administration (NMPA) to conduct its first in human clinical trial in China.

In April 2023, the study was initiated at the Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences (Peking Union Medical College), and is currently in the multi-dose incremental enrolment phase.